Abstract Little is known about long-acting injectable cabotegravir-rilpvirine (CAB/RPV-LA) discontinuation outside clinical trials. In a large clinic cohort, one in six PWH discontinued CAB/RPV-LA over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for PWH with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.
Christopoulos et al. (Fri,) studied this question.